Skip to content

Frontlight ResearchEarly access

Trial site

Aberdeen Royal Infirmary

Aberdeen, Aberdeenshire AB25 2ZN, United KingdomNot linked to an institution yet

40running trials
18closed trials

The trials here

What the 58 trials at this site are about, from their registry records.

Conditions: Type 2 diabetes8 trials
Childhood cancers6 trials
Colorectal cancer5 trials
Fatty liver disease (MASLD/MASH)4 trials
Heart failure4 trials
Lung cancer4 trials
Multiple myeloma4 trials
Chronic kidney disease3 trials
Coronary artery disease3 trials
Head and neck cancer3 trials
Prostate cancer3 trials
Stroke3 trials
and 19 more
Phase: Phase 335 trials
Phase 26 trials
Phase 2/33 trials
Phase 11 trial
Phase 1/21 trial
Phase 41 trial
Status: Recruiting20 trials
Active, not recruiting19 trials
Completed16 trials
Not yet recruiting1 trial
Terminated1 trial
Withdrawn1 trial
Lead sponsor: Eli Lilly and Company6 trials
University College, London4 trials
Boehringer Ingelheim3 trials
Novo Nordisk A/S3 trials
University of Birmingham3 trials
and 34 more

Running trials

Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· Phase 3· Bristol-Myers Squibb· Source
Contact: Andrew Duncan, Site 0365
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332· Phase 3· Eli Lilly and Company· Source
Contact: Sam Philip (principal investigator)
Recruiting
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Ashis Mukhopadhya (principal investigator)
Recruiting
Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma
NCT06762769· Phase 2· University College, London· Source
Contact: Stephanie Stone
Recruiting
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· Phase 3· Takeda· Source
Contact: Dominic Culligan (principal investigator)
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
NCT06843239· Phase 2· Zura Bio Inc· Source
Recruiting
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
NCT06435156· Phase 2· University of Dundee· Source
Contact: Ify Mordi, MBChB, MD
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Andrew Duncan (principal investigator)
Recruiting
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure
NCT05568069· University Hospital Southampton NHS Foundation Trust· Source
Contact: Dana Dawson
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer
NCT05605353· University of Aberdeen· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT05433584· Phase 4· Eli Lilly and Company· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446· Phase 2· Pfizer· Source
Recruiting
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
NCT04685616· Phase 3· University College, London· Source
Contact: Dominic Culligan
Active, not recruiting
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· Phase 3· Loxo Oncology, Inc.· Source
Recruiting
Statins for Venous Event Reduction in Patients With Venous Thromboembolism
NCT04319627· Phase 3· Ottawa Hospital Research Institute· Source
Contact: Mary-Joan Macleod (principal investigator)
Active, not recruiting
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205· Phase 2/3· BioNTech SE· Source
Active, not recruiting
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
NCT04136353· Phase 3· University of Sydney· Source
Recruiting
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study
NCT04204915· University of Leicester· Source
Contact: Dr Ciprian Dospinescu
Recruiting
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial
NCT04302870· Phase 2/3· University of Edinburgh· Source
Recruiting
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
NCT04116502· Phase 3· University of Birmingham· Source
Contact: Natalia Morelli
Active, not recruiting
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247· OncoHost Ltd.· Source
Active, not recruiting
Plasma Analysis for Response Assessment and to DIrect the manaGement of Metastatic Prostate Cancer
NCT04067713· University College, London· Source
Recruiting
Renal Adjuvant MultiPle Arm Randomised Trial
NCT03288532· Phase 3· University College, London· Source
Contact: Gordon Urquhart (principal investigator)
Recruiting
The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)
NCT03562169· Phase 3· University of Leeds· Source
Contact: Jane Tighe
Recruiting
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer
NCT04050345· Royal Marsden NHS Foundation Trust· Source
Contact: Adnan Shaukat (principal investigator)
Active, not recruiting
The British Heart Foundation SENIOR-RITA Trial
NCT03052036· Newcastle-upon-Tyne Hospitals NHS Trust· Source
Active, not recruiting
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661· Phase 2/3· Geron Corporation· Source
Active, not recruiting
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047· Phase 3· University of Birmingham· Source
Active, not recruiting
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
NCT02446405· Phase 3· University of Sydney· Source
Active, not recruiting
Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy
NCT00683319· Children's Cancer and Leukaemia Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Withdrawn
FCI Effectiveness in NAFLD Stratification
NCT05827432· NHS Grampian· Source
Completed
FCI in Post-operative Low Grade Gliomas
NCT06294418· NHS Grampian· Source
Completed
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
NCT06153693· Phase 3· Mineralys Therapeutics Inc.· Source
Completed
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06065540· Phase 3· Novo Nordisk A/S· Source
Completed
A Mouthwash Medicine for the Reduction or Prevention of Mouth Ulceration Caused by Radiotherapy for Head and Neck Cancer
NCT06669390· Phase 1· VasoDynamics Ltd· Source
Completed
Acute PresentatiOn of CoLorectaL Cancer: an internatiOnal Snapshot
NCT05641129· European Student Research Network· Source
Completed
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
NCT04660812· Phase 1/2· Arcus Biosciences, Inc.· Source
Terminated
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
NCT04698915· Phase 2· Galera Therapeutics, Inc.· Source
Completed
A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer
NCT04322539· Phase 3· Hutchison Medipharma Limited· Source
Completed
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT04255433· Phase 3· Eli Lilly and Company· Source
Completed
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
NCT03819153· Phase 3· Novo Nordisk A/S· Source
Completed
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326· Phase 3· Novo Nordisk A/S· Source
Completed
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· Phase 3· Amgen· Source
Completed
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110· Phase 3· Daiichi Sankyo· Source
Completed
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03523585· Phase 3· Daiichi Sankyo· Source
Completed
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source
Completed
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
NCT02664935· Phase 2· University of Birmingham· Source
Completed
Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours
NCT01726374· Phase 3· Institute of Cancer Research, United Kingdom· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error

Aberdeen Royal Infirmary: trial site – Frontlight Research